Accelerating
Precision Oncology

From translational research to clinical development to commercialization, we meet your needs at every stage of drug development.

Precision Medicine is Driving a New Era in Oncology Drug Development

Biopharma companies are at the forefront of introducing novel targeted therapies, redefining the therapeutic management of cancer. These treatments target the specific alterations or biomarkers of a patient, which can significantly extend progression-free survival compared with traditional chemotherapy or immunotherapy.1-4

Add a New Dimension of Insights
to Your View of Cancer

Genomics alone is a narrow view of cancer. The genome is 99.9% the same across human cells, yet certain cells behave differently. Many cellular phenotypes and behaviors are controlled by epigenetic modifications that do not harbor genetic variation, which largely remain untapped.5-8

However, among all patients with cancer, 80% are still ineligible for genomic precision medicine approaches.10

Power Your Next Breakthrough With Guardant Infinity™

Guardant Infinity is the first and only commercially available platform that combines genomic and epigenomic profiling using our proprietary nondestructive methylation technology—enabling access to epigenomic insights that are scalable from research to the clinic.11

Epigenomics examines chemical and structural modifications to DNA and histones that can affect gene expression and the regulation of biological processes that drive cancer.11,12
Learn More

Expand Patient Eligibility for Targeted Therapies

Guardant Infinity can detect promoter methylation and methylation signatures to identify more patients, including those missed by a genomic-only approach.11,13,14

Studies have shown that novel epigenomic biomarkers can reveal:

Adverse Event Prediction15-17

Response Prediction15-17

Tumor
Subtyping18

Tumor of
Origin19

Discover How Guardant Infinity Enables the Discovery of Novel Epigenomic Biomarkers

Learn More

Get in Touch With Us

  1. Shaw AT, Riely GJ, Bang Y-J, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121-1126. doi:10.1093/annonc/mdz131
  2. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41-50. doi:10.1056/NEJMoa1913662
  3. Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518-2527. doi:10.1200/JCO.19.00934
  4. Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non–small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;14(7):1233-1243. doi:10.1016/j.jtho.2019.03.007
  5. National Human Genome Research Institute. A Brief Guide to Genomics. Genome.gov. Updated August 15, 2023. Accessed March 24, 2025. https://www.genome.gov/about-genomics/fact-sheets/A-Brief-Guide-to-Genomics
  6. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148-1159. doi:10.1056/NEJMra072067
  7. LaFave L, Savage R, Buenrostro J. Single-cell epigenomics reveals mechanisms of cancer progression. Annu Rev Cancer Biol. 2022;6:167-185. doi:10.1146/annurev-cancerbio-070620-094453
  8. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi:10.1158/2159-8290.CD-21-1059
  9. Personalized Medicine Coalition. Personalized medicine at FDA: the scope & significance of progress in 2022. https://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/report.pdf
  10. Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 2018;4(8):1093-1098. doi:10.1001/jamaoncol.2018.1660
  11. Guardant Health data on file. April 2024. Guardant Health, Inc. Redwood City, CA.
  12. Al Aboud NM, Tupper C, Jialal I. Genetics, Epigenetic Mechanism. In: StatPearls. StatPearls Publishing; 2025. Accessed March 24, 2025. https://www.ncbi.nlm.nih.gov/books/NBK532999/
  13. Yen J, Chen S, Jenkins C, et al. BRCA1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy. Poster presented at: American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando, FL.
  14. Guardant Health data on file. January 29, 2025. Guardant Health, Inc. Redwood City, CA.
  15. Gordon S, Barbacioru C, Liao J, et al. Prediction of cardiac adverse events (AE) in trastuzumab treated breast cancer patients (pts) via a comprehensive genomic and DNA methylation blood-based assay. Poster presented at: AACR Annual Meeting; April 5–10, 2024; San Diego, CA. Poster 3399.
  16. Wienke S, Gordon S, Liang S, et al. Quantification of tumor fraction and outcomes association in a real-world non-small cell lung cancer (NSCLC) cohort using a tissue agnostic epigenomic circulating tumor DNA (ctDNA) assay. Poster presented at: American Association for Cancer Research Annual Meeting; April 8, 2024; San Diego, CA.
  17. Rosen E, Schonhoft JD, Silverman IM, et al. Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (Guardant Infinity™) for diagnosis of DNA damage repair (DDR) loss-of-function (LoF) and response monitoring in the TRESR and ATTACC trials. Poster presented at: AACR-NCI-EORTC (ANE) Conference; October 11-15, 2023; Boston, MA. Poster A123.
  18. Guardant Health data on file. 2025. Guardant Health, Inc. Redwood City, CA.
  19. Guardant Health data on file. 2025. Guardant Health, Inc. Redwood City, CA.